探花直播 of Cambridge - Department of Medicine

One in 3,000 people at risk of punctured lung from faulty gene 鈥� almost 100 times higher than previous estimate

cjb250 — Mon, 07 Apr 2025 23:01:05 +0000

探花直播gene in question, FLCN, is linked to a condition known as Birt-Hogg-Dub茅 syndrome, symptoms of which include benign skin tumours, lung cysts, and an increased risk of kidney cancer.

In a study published today in the journal Thorax, a team from the 探花直播 of Cambridge examined data from UK Biobank, the 100,000 Genomes Project, and East London Genes & Health 鈥� three large genomic datasets encompassing more than 550,000 people.

They discovered that between one in 2,710 and one in 4,190 individuals carries the particular variant of FLCN that underlies Birt-Hogg-Dub茅 syndrome. But curiously, whereas patients with a diagnosis of Birt-Hogg-Dub茅 syndrome have a lifetime risk of punctured lung of 37%, in the wider cohort of carriers of the genetic mutation this was lower at 28%. Even more striking, while patients with Birt-Hogg-Dub茅 syndrome have a 32% of developing kidney cancer, in the wider cohort this was only 1%.

Punctured lung 鈥� known as pneumothorax 鈥� is caused by an air leak in the lung, resulting in painful lung deflation and shortness of breath.聽Not every case of punctured lung is caused by a fault in the FLCN gene, however. Around one in 200 tall, thin young men in their teens or early twenties will experience a punctured lung, and for many of them the condition will resolve itself, or doctors will remove air or fluid from their lungs while treating the individual as an outpatient; many will not even know they have the condition.

If an individual experiences a punctured lung and doesn鈥檛 fit the common characteristics 鈥� for example, if they are in their forties 鈥� doctors will look for tell-tale cysts in the lower lungs, visible on an MRI scan. If these are present, then the individual is likely to have Birt-Hogg-Dub茅 syndrome.

Professor Marciniak is a researcher at the 探花直播 of Cambridge and an honorary consultant at Cambridge 探花直播 Hospitals NHS Foundation Trust and Royal Papworth Hospital NHS Foundation Trust. He co-leads the UK鈥檚 first Familial Pneumothorax Rare Disease Collaborative Network, together with Professor Kevin Blyth at Queen Elizabeth 探花直播 Hospital and 探花直播 of Glasgow. 探花直播aim of the Network is to optimise the care and treatment of patients with rare, inherited forms of familial pneumothorax, and to support research into this condition.聽

Professor Marciniak said: 鈥淚f an individual has Birt-Hogg-Dub茅 syndrome, then it鈥檚 very important that we鈥檙e able to diagnose it, because they and their family members may also be at risk of kidney cancer.

鈥� 探花直播good news is that the punctured lung usually happens 10 to 20 years before the individual shows symptoms of kidney cancer, so we can keep an eye on them, screen them every year, and if we see the tumour it should still be early enough to cure it.鈥�

Professor Marciniak says he was surprised to discover that the risk of kidney cancer was so much lower in carriers of the faulty FLCN gene who have not been diagnosed with Birt-Hogg-Dub茅 syndrome.

鈥淓ven though we鈥檝e always thought of Birt-Hogg-Dub茅 syndrome as being caused by a single faulty gene, there鈥檚 clearly something else going on,鈥� Professor Marciniak said. 鈥� 探花直播Birt-Hogg-Dub茅 patients that we've been caring for and studying for the past couple of decades are not representative of when this gene is broken in the wider population. There must be something else about their genetic background that鈥檚 interacting with the gene to cause the additional symptoms.鈥�

探花直播finding raises the question of whether, if an individual is found to have a fault FLCN gene, they should be offered screening for kidney cancer. However, Professor Marciniak does not believe this will be necessary.

鈥淲ith increasing use of genetic testing, we will undoubtedly find more people with these mutations,鈥� he said, 鈥渂ut unless we see the other tell-tale signs of Birt-Hogg-Dub茅 syndrome, our study shows there's no reason to believe they鈥檒l have the same elevated cancer risk.鈥�

探花直播research was funded by the Myrovlytis Trust, with additional support from the National Institute for Health and Care Research Cambridge Biomedical Research Centre.

Katie Honeywood, CEO of the Myrovlytis Trust, said: " 探花直播Myrovlytis Trust are delighted to have funded such an important project. We have long believed that the prevalence of Birt-Hogg-Dub茅 syndrome is far higher than previously reported. It highlights the importance of genetic testing for anyone who has any of the main symptoms associated with BHD including a collapsed lung. And even more so the importance of the medical world being aware of this condition for anyone who presents at an emergency department or clinic with these symptoms. We look forward to seeing the impact this projects outcome has on the Birt-Hogg-Dub茅 and wider community."

Reference
Yngvadottir, B et al. Inherited predisposition to pneumothorax: Estimating the frequency of Birt-Hogg-Dub茅 syndrome from genomics and population cohorts. Thorax; 8 April 2025; DOI: 10.1136/thorax-2024-221738

As many as one in 3,000 people could be carrying a faulty gene that significantly increases their risk of a punctured lung, according to new estimates from Cambridge researchers. Previous estimates had put this risk closer to one in 200,000 people.

If an individual has Birt-Hogg-Dub茅 syndrome, then it鈥檚 very important that we鈥檙e able to diagnose it, because they and their family members may also be at risk of kidney cancer

Stefan Marciniak

wildpixel (Getty Images)

Chest pain

探花直播text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright 漏探花直播 of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways 鈥� on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

Opinion: AI can transform health and medicine

cjb250 — Mon, 07 Apr 2025 08:00:37 +0000

AI has the potential to transform health and medicine. It won't be straightforward, but if we get it right, the benefits could be enormous. Andres Floto, Mihaela van der Schaar and Eoin McKinney explain.

Prioritise vaccine boosters for vulnerable immunocompromised patients, say scientists

cjb250 — Wed, 12 Feb 2025 19:00:46 +0000

探花直播findings, published today in Science Advances, suggest that such individuals will need regular vaccine boosters to protect them and reduce the risk of infections that could be severe and also lead to new 鈥榲ariants of concern鈥� emerging.

Almost 16 million people worldwide are estimated to have died from Covid-19 during 2020 and 2021, though nearly 20 million deaths are thought to have been prevented as a result of the rapid rollout of vaccines against SARS-CoV-2, the virus that caused the pandemic.

During the pandemic, researchers discovered that immunocompromised individuals had difficulty clearing the virus, even when vaccinated. These are people whose immune systems are not functioning correctly, either as a direct result of disease or because they are on medication to dampen down their immune systems, for example to prevent organ transplant rejection. This meant that their infections lasted longer, giving the virus more opportunities to mutate.

Research from early in the pandemic showed that chronic infections can give rise to variants of concern that can then cause new waves of infection in the wider population.

When an individual is vaccinated, their immune systems produce antibodies that recognise and launch an attack on the virus. Such a process is known as seroconversion. Additional 鈥榖ooster鈥� vaccinations increase seroconversion and hence the likelihood of clearing infection.

However, although most immunocompromised individuals will have received three or more doses of the Covid-19 vaccine, they still account for more than a fifth of hospitalisations, admissions to intensive care units, and overall deaths associated with the disease.

To see why this is the case, scientists at the Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID) at the 探花直播 of Cambridge examined immunocompromised individuals who had been vaccinated against Covid-19. These patients, recruited from Cambridge 探花直播 Hospitals NHS Foundation Trust, were living with vasculitis, a group of disorders that cause inflammation of blood vessels. Data from this group was compared against individuals who were not immunocompromised.

Treatments for vasculitis rely on immunosuppressant medicines. These include drugs such as rituximab, which depletes the number of B-cells in the body 鈥� but B-cells are the immune cells responsible for producing antibodies. As such, these individuals are a severely at-risk population.

When the researchers analysed bloods samples from the vasculitis patients, they found that even though vaccination induced seroconversion, this in itself was not always sufficient to neutralise the virus. Every immunocompromised individual required at least three doses of the vaccine to protect them across a range of variants up to and include Omicron (the variant that appeared towards the end of 2021 and caused a new wave of infections). In some cases, even four vaccinations were not sufficient to adequately protect them.

Kimia Kamelian, a Gates Cambridge Scholar at CITIID and St Edmund's College, Cambridge, said: 鈥淲e know that immunocompromised individuals are particularly vulnerable to diseases such as Covid-19 because their immune systems struggle to clear infections. Vaccinations offer some protection, but our study shows that only repeated vaccinations 鈥� often four or more 鈥� offer the necessary protection.鈥�

Professor Ravi Gupta, also from CITIID and a Fellow at Homerton College, Cambridge, added: 鈥淭his of course has implications for the individual, who is more likely to have prolonged infection and a much greater risk of severe infection, but it also gives the virus multiple opportunities to mutate.

鈥淲e know from our previous work that at least some of the variants of concern probably emerged during chronic infections. That鈥檚 why these individuals must be given priority for updated vaccines against new variants.鈥�

探花直播research was funded by Wellcome, Gates Cambridge, Addenbrooke鈥檚 Charitable Trust and Vasculitis UK, with additional support by the National Institute for Health and Care Research Cambridge Biomedical Research Centre.

Reference
Kamelian, K et al. Humoral responses to SARS-CoV-2 vaccine in vasculitis-related immune suppression. Sci Adv; 12 Feb 2025; DOI: 10.1126/sciadv.adq3342

Vaccinations alone may not be enough to protect people with compromised immune systems from infection, even if the vaccine has generated the production of antibodies, new research from the 探花直播 of Cambridge has shown.

We know that immunocompromised individuals are particularly vulnerable to diseases such as Covid-19 because their immune systems struggle to clear infections

Kimia Kamelian

NoSystem images

Vaccination of an senior male

Yes

探花直播Cambridge Awards 2024 for Research Impact and Engagement

zs332 — Mon, 03 Feb 2025 10:27:01 +0000

Meet the winner of the Cambridge Awards 2024 for Research Impact and Engagement and learn more about their projects.

Professor Duncan Richards appointed as Head of Department of Medicine

Anonymous — Fri, 06 Dec 2024 16:59:07 +0000

Professor Richards joins Cambridge from the 探花直播 of Oxford, where he has been since 2019. His particular research interest is the demonstration of clinical proof of concept of novel therapeutics through the application of experimental medicine techniques, especially human challenge studies.

As Climax Professor of Clinical Therapeutics, director of the Oxford Clinical Trial Research Unit (OCTRU), and the NIHR Oxford Clinical Research Facility, he led a broad portfolio focused on new medicines for multiple conditions. His focus has been the acceleration of promising new drug treatments through better decision-making in early phase clinical trials.

Professor Richards also brings with him a wealth of experience in a number of Pharmaceutical R&D clinical development roles. In 2003 he joined GSK and held a number of roles of increasing responsibility, latterly as Head of Clinical Pharmacology and Experimental Medicine, including directorship of GSK鈥檚 phase 1 and experimental medicine unit in Cambridge (CUC).

Commenting on his appointment, Professor Richards said: 鈥淎s a clinical pharmacologist, I have been fortunate to work across a broad range of therapeutic areas over the years. I am excited by the breadth and depth of expertise within the Department of Medicine and look forward to working with the first-class scientific team. My goal is to work with the Department team, the Clinical School, and hospitals to maximise the impact of the important work taking place in Cambridge.鈥�

Members of the department鈥檚 leadership team are looking forward to the continued development of the department under Professor Richards, building on its legacy of collaboration and groundbreaking translational research to drive our future success.

Professor Mark Wills, Interim Head of Department of Medicine, said: 鈥淒uncan brings to his new role a fantastic breadth of experience, which encompasses his clinical speciality in pharmacology, extensive experience of working within the pharmaceutical industry R&D at senior levels and most recently establishing academic clinical trials units and human challenge research facilities.

鈥淚 am very excited to welcome Duncan to the Department and looking forward to working with him, as he takes on the role of delivering of the Department of Medicine鈥檚 vision to increase the efficacy of translation of its world class fundamental research, and its impact upon clinical practice and patient wellbeing.鈥�

Menna Clatworthy, Professor of Translational Immunology and Director of the Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID), said: "Duncan has a wealth of leadership experience in biomedicine, in both academia and pharma. That skillset will be invaluable in ensuring the Department of Medicine continues to deliver world-leading research to transform patient outcomes."

Charlotte Summers, Professor of Intensive Care Medicine and Director of the Victor Phillip Dahdaleh Heart & Lung Research Institute, said: 鈥淒uncan鈥檚 exemplary track record of translating fundamental scientific discoveries into therapies that benefit patients will help us further increase the impact of our research as we continue our mission to improve human health.鈥�

探花直播appointment underpins the recently announced five-year collaboration between GSK and the 探花直播 of Cambridge, the Cambridge-GSK Translational Immunology Collaboration (CG-TIC). 探花直播拢50 million investment will accelerate research and development in kidney and respiratory diseases to improve patient outcomes.

Professor Richards will assume the role in February 2025, replacing Interim Head of Department Dr Mark Wills who was appointed after the departure of Professor Ken Smith in January 2024.聽 Dr Wills will continue as Director of Research and Deputy Head of the Department of Medicine as well as leading his research group.聽

Professor Richards trained in medicine at Oxford 探花直播 and after junior doctor roles in London, he returned to Oxford as Clinical Lecturer in Clinical Pharmacology. His DM thesis research was on a translational model using platelet ion flux to interrogate angiotensin biology and he is author of the Oxford Handbook of Practical Drug Therapy and the 3rd edition of Drug Discovery and Development.

Professor Richards has been a core member of the UK COVID-19 Therapeutics Advisory Panel. He is a member of the Oxford Bioescalator Management Board, UK Prix Galien Prize Committee, and the therapeutic advisory committee of several national platform clinical trials.

Professor Duncan Richards has today been announced as the new Head of the Department of Medicine at the 探花直播 of Cambridge.

I am excited by the breadth and depth of expertise within the Department of Medicine and look forward to working with the first-class scientific team

Duncan Richards

Yes

10 Cambridge spinouts changing the story of cancer

skbf2 — Thu, 17 Oct 2024 12:57:43 +0000

10 Cambridge spinouts聽on putting their research into practice to improve outcomes for cancer patients - and why Cambridge is a great place to do this.聽聽聽聽

Monoclonal antibodies offer hope for tackling antimicrobial resistance

cjb250 — Mon, 16 Sep 2024 10:31:11 +0000

A team lead by researchers at the 探花直播 of Cambridge has developed a monoclonal antibody drug, using a technique involving genetically engineered mice, that may help prevent infection from Acinetobacter baumannii, a bacteria associated with hospital-acquired infections, which is particularly common in Asia.

A. baumannii bacteria can cause life-threatening respiratory illness and sepsis in vulnerable individuals, particularly in newborn babies whose immune systems have not fully developed. It is usually spread through contaminated surfaces, medical equipment and via contact with others. In recent years infections with strains of this bacteria that are resistant to almost every antibiotic available have become common.

Professor Stephen Baker from the Cambridge Institute of Therapeutic Immunology and Infectious Disease at the 探花直播 of Cambridge said 鈥�A. baumannii is good at sticking to medical equipment, and if people are vulnerable or don't have a particularly well-developed immune system, they can succumb to this infection and get aggressive pneumonia requiring ventilation 鈥� and in many cases, the patients can acquire the infection from the ventilation itself.

鈥� 探花直播bacteria are naturally resistant to many antimicrobials, but as they鈥檙e now found in hospitals, they鈥檝e acquired resistance to almost everything we can use. In some hospitals in Asia, where the infections are most common, there isn't a single antibiotic that will work against them. They鈥檝e become impossible to treat.鈥�

In a study published today in Nature Communications, the team produced monoclonal antibodies using transgenic mice 鈥� mice that have been genetically-engineered to have a human-like immune system, producing human antibodies instead of mouse antibodies. They went on to show that these monoclonal antibodies were able prevent infection with A. baumannii derived from clinical samples.

Monoclonal antibodies are a growing area of medicine, commonly used to treat conditions including cancer (for example, Herceptin for treating some breast cancers) and autoimmune disease (for example, Humira for treating rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis).

Usually, monoclonal antibodies are developed from the antibodies of patients who have recovered from an infection, or they are designed to recognise and target a particular antigen. For example, monoclonal antibodies targeting the 鈥榮pike protein鈥� of the SARS-CoV-2 coronavirus were explored as a way of treating COVID-19.

In the approach taken by the Cambridge team, however, transgenic mice were exposed to the outer membrane of A. baumannii bacteria, triggering an immune response. 探花直播researchers then isolated almost 300 different antibodies and tested which of these was the most effective at recognising live bacteria, identifying the single monoclonal antibody mAb1416 as the best.

Professor Baker said: 鈥淯sing this method, we don't infect the mice with the live bacteria, but we instead immunise them using multiple different elements and let the mouse鈥檚 immune system work out which ones to develop antibodies against. Because these mice have 鈥榟umanised鈥� immune systems, we wouldn鈥檛 then need to reengineer the antibodies to work in humans.鈥�

探花直播team treated mice with mAb1416, and 24 hours later exposed them to A. baumannii isolated from a child with sepsis in an intensive care unit. They found that those mice treated with the drug saw a significant reduction in bacterial load in their lungs a further 24 hours later, compared to mice that were not treated.

All of the isolates used to produce and test the monoclonal antibodies were from patients in Ho Chi Minh City, Vietnam, but the isolate used to test mAb1416 was taken from a patient ten years later than the other isolates. This is important because it shows that mAb1416 was protective against A. baumannii bacteria that may have evolved over time.

Professor Baker said: 鈥淯sing this technique, you can take any bacterial antigen or cocktail of antigens, rather than waiting for somebody that's recovered from a particular infection 鈥� who you assume has developed an appropriate antibody response 鈥� give it to the mice and extract the antibodies you think are the most important.鈥�

More work is now needed to understand the mechanism by which mAb1416 protects against infection, as this could allow the team to develop an even more effective treatment. Any potential new drug will then need to be tested in safety trials in animals before being trialled in patients.

Professor Baker added: 鈥淲e know that monoclonal antibodies are safe and that they work, and the technology exists to produce them 鈥� what we have done is identify how to hit bacteria with them. Apart from the cost effectiveness, there's no reason why this couldn鈥檛 become a medicine within a few years. Given the emergency presented by antimicrobial resistance, this could become a powerful new weapon to fight back.鈥�

探花直播research was funded by the Bill & Melinda Gates Foundation, the UK Medical Research Council Newton Fund, the Viet Nam Ministry of Science and Technology, and Wellcome.

Professor Baker is a fellow at Wolfson College, Cambridge.

Reference
Baker, S, Krishna, A & Higham, S. Exploiting human immune repertoire transgenic mice to identify protective monoclonal antibodies against an extensively antimicrobial resistant nosocomial bacterial pathogen. Nat Comms; 12 Sept 2024; DOI: 10.1038/s41467-024-52357-8

Monoclonal antibodies 鈥� treatments developed by cloning a cell that makes an antibody 鈥� could help provide an answer to the growing problem of antimicrobial resistance, say scientists.

We know that monoclonal antibodies are safe and that they work, and the technology exists to produce them 鈥� what we have done is identify how to hit bacteria with them

Stephen Baker

TopMicrobialStock (Getty Images)

A Petri dish with a culture of the Superbug Acinetobacter baumannii next to antibiotics

Yes

High cholesterol levels at a young age significant risk factor for atherosclerosis

cjb250 — Wed, 04 Sep 2024 15:00:18 +0000

探花直播research also suggests that people who are taking lipid-lowering drugs such as statins to lower their cholesterol levels should remain on them, even if their cholesterol levels have fallen, as stopping treatment could increase their risk of atherosclerosis.

Atherosclerosis is one of the major causes of heart and circulatory disease. It involves the hardening and narrowing of the vessels that carry blood to and from the heart. It is caused by the build-up of abnormal material called plaques 鈥� collections of fat, cholesterol, calcium and other substances circulating in the blood.

Atherosclerosis is largely considered a disease of the elderly and so most screening, prevention and intervention programmes primarily target those with high cholesterol levels, generally after the age of 50.

But in a study published today in Nature, a team led by scientists at the 探花直播 of Cambridge shows that high cholesterol levels at a younger age 鈥� particularly if those levels fluctuate 鈥� can be even more damaging than high cholesterol levels that only begin in later life.

To study the mechanisms that underlie atherosclerosis, scientists often use animal modes, such as mice. 探花直播mice will typically be fed a high fat diet for several weeks as adults to see how this leads to the build up of the plaques characteristic of the condition.

Professor Ziad Mallat and colleagues at the Victor Phillip Dahdaleh Heart and Lung Research Institute at the 探花直播 of Cambridge decided to explore a different approach 鈥� to see whether giving mice the same amount of high fat food but spread over their lifetime changed their atherosclerosis risk.

鈥淲hen I asked my group and a number of people who are experts in atherosclerosis, no one could tell me what the result would be,鈥� said Professor Mallat, a British Heart Foundation (BHF) Professor of Cardiovascular Medicine.

鈥淪ome people thought it would make no difference, others thought it would change the risk. In fact, what we found was that an intermittent high fat diet starting while the mice were still young 鈥� one week on, a few weeks off, another week on, and so on 鈥� was the worst option in terms of atherosclerosis risk.鈥�

Armed with this information, his team turned to the Cardiovascular Risk in聽Young Finns Study, one of the largest follow-up studies into cardiovascular risk from childhood to adulthood. Participants recruited in the 1980s returned for follow-up over the subsequent decades, and more than 2,000 of them had received ultrasound scans of their carotid arteries when they were aged around 30 years and again at around 50 years.

Analysing the data, the team found that those participants who had been exposed to high cholesterol levels as children tended to have the biggest build of plaques, confirming the findings in mice.

鈥淲hat this means is that we shouldn鈥檛 leave it until later in life before we start to look at our cholesterol levels,鈥� Professor Mallat said. 鈥淎therosclerosis can potentially be prevented by lowering cholesterol levels, but we clearly need to start thinking about this much earlier on in life than we previously thought.鈥�

探花直播mouse studies showed that fluctuating levels of cholesterol appeared to cause the most damage. Professor Mallat says this could explain why some people who are on statins but do not take them regularly remain at an increased risk of heart attack.

鈥淚f you stop and start your statin treatment, your body is being exposed to a yo-yo of cholesterol, which it doesn鈥檛 like, and it seems this interferes with your body鈥檚 ability to prevent the build-up of plaques,鈥� he added.

探花直播reason why this is so damaging may come down to the effect that cholesterol has on specific types of immune cells known as 鈥榬esident arterial macrophages鈥�. These reside in your arteries, helping them to clear damaged cells and fatty molecules known as lipids, which include cholesterol, and stopping the build-up of plaques.

When the team examined these macrophages in their mouse models, they found that high cholesterol levels 鈥� and in particular, fluctuating cholesterol levels 鈥� changed them physically and altered the activity of their genes. This meant that the cells were no longer protective, but were instead detrimental, accelerating atherosclerosis.

探花直播research was funded by the British Heart Foundation.

Reference
Takaoka, M et al. Early intermittent hyperlipidaemia alters tissue macrophages to boost atherosclerosis. Nature; 4 Sept 2024; DOI: 10.1038/s41586-024-07993-x

Our risk of developing atherosclerosis 鈥� 鈥榝urring鈥� of the arteries 鈥� can begin much earlier in life than was previously thought, highlighting the need to keep cholesterol levels low even when we are young, new research has discovered.

Atherosclerosis can potentially be prevented by lowering cholesterol levels, but we clearly need to start thinking about this much earlier on in life

Ziad Mallat

SolStock (Getty Images)

Teenagers eating pizza by the river

Yes